Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment

Basit Öğe Kaydı
dc.contributor.authorEkici, Sinan
dc.contributor.authorCengiz, Melahat
dc.contributor.authorTuran, Guven
dc.contributor.authorAlis, Esra Ergun
dc.date.accessioned2024-07-12T21:49:56Z
dc.date.available2024-07-12T21:49:56Z
dc.date.issued2012en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractThis study aims to scrutinize the hospitalized patients with the diagnosis of acute prostatitis after transrectal ultrasound-guided biopsy of the prostate (TRUSBP) focusing their history of previous antibiotic use, clinical pictures, microbiologic features, and resistance patterns of the isolates. A retrospective evaluation of the records between 2005 and 2010 revealed 13 patients. All patients received ciprofloxacin 500 mg twice a day starting from the day before TRUSBP for 5 days. Positive 13 urine and 7 blood samples (Escherichia coli in 12 patients, Enterococcus species in one) were evaluated for resistance patterns. All were resistant to fluoroquinolones. Extended spectrum beta-lactamase producing E. coli isolated in 4 patients were treated with carbapenems. Empirical ceftriaxone was shifted to carbapenem (4 patients), vancomycin (1 patient). Empirical carbapenem was maintained in 5 patients. Seven patients with elevated PSA received fluoroquinolones for 4 weeks before TRUSBP on the assumption that they had subclinical infectious prostatitis. Previous exposure to fluoroquinolones did not lead to important differences in respect to the studied parameters. The prompt initiation of effective treatment is essential to decrease morbidity and mortality. Empirical treatment would be a second or third generation cephalosporins, or carbapenems according to clinical severity of patients.en_US
dc.identifier.doi10.1007/s11255-011-9980-3
dc.identifier.endpage27en_US
dc.identifier.issn0301-1623
dc.identifier.issue1en_US
dc.identifier.pmid21547465en_US
dc.identifier.scopus2-s2.0-84861162543en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage19en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s11255-011-9980-3
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8111
dc.identifier.volume44en_US
dc.identifier.wosWOS:000299080500005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofINTERNATIONAL UROLOGY AND NEPHROLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY01314
dc.subjectExtended spectrum beta lactamasesen_US
dc.subjectProphylaxisen_US
dc.subjectAntibiotic resistanceen_US
dc.subjectAcute prostatitisen_US
dc.subjectProstate biopsyen_US
dc.titleFluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatmenten_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu